bupropion sold brand name wellbutrin among others atypical antidepressant primarily used treat major depressive disorder support smoking also popular addon medication cases incomplete response firstline selective serotonin reuptake inhibitor ssri bupropion several features distinguish antidepressants usually cause sexual associated weight effective ssris improving symptoms hypersomnia bupropion particularly immediate release formulation carries higher risk seizure many antidepressants hence caution recommended patients history seizure common adverse effects bupropion greatest difference placebo dry mouth nausea constipation insomnia anxiety tremor excessive verification raised blood pressure rare serious side effects include liver risk bupropion use pregnancy may associated increased odds congenital heart bupropion acts reuptake inhibitor nicotinic receptor however effects dopamine chemically bupropion aminoketone belongs class substituted cathinones generally substituted amphetamines substituted bupropion invented nariman mehta worked burroughs wellcome first approved medical use united states bupropion originally called generic name amfebutamone renamed commonly prescribed medication united states million world health organizations list essential evidence overall supports efficacy bupropion placebo treatment however quality evidence metaanalyses report bupropion atmost small effect size one metaanalysis reported large effect however methodological limitations metaanalysis including using subset five trials effect size calculation substantial variability effect sizes selected led authors state findings area interpreted extreme general lack inclusion unpublished trials unpublished trials likely negative metaanalyses included unpublished evidence suggests efficacy bupropion depression similar autumn winter months bupropion prevents development depression recurring seasonal affective disorder participants bupropion experienced major depressive episode vs bupropion also improves depression bipolar disorder efficacy risk affective switch similar bupropion several features distinguish antidepressants instance unlike majority antidepressants usually cause sexual dysfunction occurrence sexual side effects different bupropion treatment associated weight gain contrary majority studies observed significant weight loss bupropiontreated bupropion treatment also associated sleepiness may produced bupropion effective selective serotonin reuptake inhibitors ssris improving symptoms hypersomnia fatigue depressed bupropion effective treatment anxious depression contrary common belief exacerbate anxiety effectiveness bupropion anxious depression equivalent ssris case depression low moderate anxiety whereas ssris show modest effectiveness advantage terms response rates depression high addition bupropion prescribed ssri common strategy people respond supported clinical however appears inferior addition atypical antipsychotic explanation needed prescribed aid smoking cessation bupropion reduces severity craving nicotine withdrawal depressed mood irritability difficulty concentrating increased initially bupropion slows weight gain often occurs first weeks quitting smoking time however effect becomes bupropion treatment course lasts seven twelve weeks patient halting use tobacco ten days course effectiveness bupropion maintaining abstinence smoking declines time tobacco abstinence months one unclear whether extending bupropion treatment helps prevent relapse overall six months therapy bupropion increases likelihood quitting smoking approximately fold compared placebo respect bupropion effective nicotine replacement therapy inferior varenicline combining bupropion nicotine replacement therapy improve quitting children adolescents use bupropion smoking cessation appear offer significant evidence use aid smoking cessation pregnant women united states treatment attention deficit hyperactivity disorder adhd approved indication bupropion mentioned current guideline adhd treatment american academy systematic reviews bupropion treatment adhd adults children note bupropion may effective adhd warn conclusion interpreted caution clinical trials low quality due small sizes risk similarly atomoxetine bupropion delayed onset action adhd several weeks treatment required therapeutic contrast stimulants amphetamine methylphenidate immediate onset effect bupropion less likely antidepressants cause sexual range studies indicate bupropion produces fewer sexual side effects antidepressants actually help alleviate sexual including sexual dysfunction induced ssri also small studies suggesting bupropion bupropiontrazodone combination may improve measures sexual function women hypoactive sexual desire disorder hsdd according expert consensus recommendation international society study womens sexual health bupropion considered offlabel treatment hsdd despite limited safety efficacy likewise systematic review metaanalysis bupropion sexual desire disorder women reported although data limited bupropion appeared dosedependently effective bupropion used treating obesity period months results average weight loss kg lbs much different weight loss produced several weightloss medications sibutramine combination drug naltrexonebupropion approved us food drug administration fda treatment bupropion effective treatment cocaine showing promise reducing drug use light methamphetamine based studies indicating bupropion lowers level inflammatory mediator tnfalpha suggestions might useful treating inflammatory bowel disease psoriasis autoimmune conditions little clinical evidence bupropion effective treating chronic low back bupropion available oral tablet number different formulated mostly hydrochloride salt also lesser extent hydrobromide available forms bupropion hydrochloride include ir instantrelease tablets mg sr sustainedrelease tablets mg xl extendedrelease tablets ir formulation generally administered thrice daily sr formultion twice daily xl formulation daily marketed form bupropion hydrobromide aplenzin extendedrelease oral tablet taken daily mg equivalent mg bupropion addition singledrug formulations bupropion formulated combinations including naltrexonebupropion contrave mg extendedrelease tablets dextromethorphanbupropion auvelity mg tablets drug label advises bupropion prescribed individuals epilepsy conditions lower seizure threshold anorexia nervosa bulimia nervosa benzodiazepine alcohol withdrawal avoided individuals taking monoamine oxidase inhibitors maois label recommends caution exercised treating people liver damage severe kidney disease severe hypertension children adolescents young adults due increased risk suicidal common adverse effects bupropion greatest difference placebo dry mouth nausea constipation insomnia anxiety tremor excessive bupropion highest incidence insomnia secondgeneration antidepressants apart also associated increased risk bupropion raises blood pressure people one study showed average rise mm hg systolic blood pressure prescribing information notes hypertension sometimes severe observed people taking bupropion without preexisting safety bupropion people cardiovascular conditions general cardiovascular safety profile remain unclear due lack seizure rare serious adverse effect bupropion strongly dosedependent immediate release preparation seizure incidence dose mg per day incidence climbs almost tenfold higher recommended dose comparison incidence unprovoked seizure general population risk seizure variety antidepressants generally recommended cases liver toxicity leading death liver transplantation reported bupropion considered one several antidepressants greater risk prescribing information warns bupropion triggering angleclosure glaucoma hand bupropion may decrease risk development open angle bupropion use mothers first trimester pregnancy associated increase odds congenital heart defects bupropion rarely associated instances fda requires antidepressants including bupropion carry boxed warning stating antidepressants may increase risk suicide people younger warning based statistical analysis conducted fda found increase suicidal thought behavior children adolescents increase age analysis fda combined results trials antidepressants order obtain statistically significant results considered isolation bupropion statistically different bupropion prescribed smoking cessation results increase risk psychiatric side effects particular anxiety increase insomnia increase evidence insufficient determine whether bupropion associated suicides suicidal rare cases bupropioninduced psychosis may develop associated higher doses bupropion many cases described higher recommended doses concurrent antipsychotic medication appears cases psychotic symptoms eliminated reducing dose ceasing treatment adding antipsychotic although studies lacking handful case reports suggest abrupt discontinuation bupropion may cause antidepressant discontinuation bupropion considered moderately dangerous according analysis us national poison data system adjusted number prescriptions bupropion venlafaxine two new generation antidepressants excluding tricyclic antidepressants result highest mortality significant overdoses seizures reported third cases serious effects include hallucinations loss consciousness abnormal heart rhythms bupropion one several kinds pills taken overdose fever muscle rigidity muscle damage hypertension hypotension stupor coma respiratory failure reported people recover people died multiple uncontrolled seizures myocardial since bupropion metabolized hydroxybupropion enzyme drug interactions inhibitors possible includes medications paroxetine sertraline norfluoxetine active metabolite fluoxetine diazepam clopidogrel orphenadrine expected result increase bupropion decrease hydroxybupropion blood concentration reverse effect decrease bupropion increase hydroxybupropion expected inducers carbamazepine clotrimazole rifampicin ritonavir st johns wort indeed carbamazepine decreases exposure bupropion increases exposure hydroxybupropion ritonavir lopinavirritonavir efavirenz shown decrease levels bupropion andor ticlopidine clopidogrel potent inhibitors found considerably increase bupropion levels well decrease levels metabolite bupropion metabolites inhibitors hydroxybupropion responsible inhibition additionally bupropion metabolites may decrease expression liver end effect significant slowing clearance drugs metabolized instance bupropion found increase areaunderthecurve desipramine substrate bupropion also found increase levels atomoxetine decreasing exposure main metabolite another example ratio dextromethorphan drug mainly metabolized major metabolite dextrorphan increased approximately administered people treated mgday people bupropion given mdma increase exposure drugs observed enhanced mood decreased heart rate effects interactions substrates metoprolol imipramine also reported however notable exception bupropion seem affect concentrations substrates fluoxetine bupropion lowers seizure threshold therefore potentially interact medications also lower antipsychotics tricyclic antidepressants theophylline systemic prescribing information recommends minimizing use alcohol since rare cases bupropion reduces alcohol caution observed combining bupropion monoamine oxidase inhibitor maoi may result hypertensive mechanism action bupropion treatment depression indications however thought related fact bupropion reuptake inhibitor ndri antagonist several nicotinic acetylcholine uncertain whether bupropion releasing pharmacological actions bupropion substantial degree due active metabolites hydroxybupropion threohydrobupropion erythrohydrobupropion present blood plasma comparable much higher fact bupropion could accurately conceptualized prodrug overall action metabolites particularly one enantiomer sshydroxybupropion also characterized inhibition norepinephrine dopamine reuptake nicotinic antagonism see chart bupropion meaningful direct activity variety receptors including α βadrenergic dopamine serotonin histamine muscarinic acetylcholine occupancy dopamine transporter dat bupropion mgday metabolites human brain measured several positron emission tomography pet studies approximately mean occupancy range comparison ndri methylphenidate therapeutic doses thought occupy greater dat accordance low dat occupancy measurable dopamine release human brain detected bupropion one mg dose pet bupropion also shown increase striatal though unknown effect pronounced findings raise questions role dopamine reuptake inhibition pharmacology bupropion suggest actions may responsible therapeutic research needed data available occupancy norepinephrine transporter net bupropion however due increased exposure hydroxybupropion bupropion higher affinity net bupropions overall pharmacological profile humans may end making effectively norepinephrine reuptake inhibitor dopamine reuptake accordingly clinical effects bupropion consistent noradrenergic activity dopaminergic bupropion found mixture antiinflammatory proinflammatory activity modulation immune one mechanism underlying effects may reduced levels proinflammatory cytokine tumor necrosis factor alpha catecholaminergic actions bupropion may involved immunomodulatory oral administration bupropion rapidly completely absorbed reaching peak blood plasma concentration hours tmax sustained release sr extended release xl formulations designed slow absorption resulting tmax hours hours absolute bioavailability bupropion unknown presumed low due firstpass metabolism relative bioavailability formulations xl formulation lower bioavailability compared sr formulation immediate release bupropion metabolized body variety pathways oxidative pathways cytochrome isoenzymes leading rr sshydroxybupropion lesser degree leading reductive pathways dehydrogenase type liver intestine leading threohydrobupropion yet unknown enzyme leading metabolism bupropion highly variable effective doses bupropion received persons ingest amount drug may differ much times halflife hours effective doses hydroxybupropion may differ much times halflife based researchers advocated monitoring blood level bupropion bupropion aminoketone belongs class substituted cathinones general class substituted clinically used bupropion racemic mixture two enantiomers sbupropion rbupropion although optical isomers bupropion separated rapidly racemize physiological reported cases falsepositive urine amphetamine tests persons taking synthesized two chemical steps starting alpha position adjacent ketone first brominated followed nucleophilic displacement resulting alphabromoketone tbutylamine treated hydrochloric acid give bupropion hydrochloride salt overall bupropion invented nariman mehta burroughs wellcome glaxosmithkline us patent granted approved us food drug administration fda antidepressant december marketed name however significant incidence seizures originally recommended dosage mgday caused withdrawal drug subsequently risk seizures found highly dosedependent bupropion reintroduced market lower maximum recommended daily dose fda approved sustainedrelease formulation alcoholresistant bupropion called wellbutrin sr intended taken twice day compared three times day immediaterelease fda approved another sustainedrelease formulation called wellbutrin xl intended oncedaily wellbutrin sr xl available generic form united states canada bupropion approved fda use smoking cessation aid name wellbutrin xl similarly approved treatment seasonal affective october two providers consumer information nutritional products supplements consumerlabcom peoples pharmacy released results comparative tests different brands peoples pharmacy received multiple reports increased side effects decreased efficacy generic bupropion prompted ask consumerlabcom test products question tests showed one generic versions wellbutrin xl mg sold budeprion xl mg didnt perform brandname pill fda investigated complaints concluded budeprion xl equivalent wellbutrin xl regard bioavailability bupropion main active metabolite hydroxybupropion fda also said coincidental natural mood variation likely explanation apparent worsening depression switch wellbutrin xl budeprion october however fda reversed opinion announcing budeprion xl mg fails demonstrate therapeutic equivalence wellbutrin xl fda test bioequivalence generic versions wellbutrin xl mg requested four manufacturers submit data question fda march october fda made determinations formulations manufacturers april fda approved formulation bupropion hydrobromide salt instead hydrochloride salt sold name aplenzin fda issued health advisory warning prescription bupropion smoking cessation associated reports unusual behavior changes agitation hostility people according advisory become depressed depression worsen thoughts suicide dying attempted advisory based review antismoking products identified reports suicidal adverse events bupropion ten based results followup trials warning removed us justice department announced glaxosmithkline agreed plead guilty pay billion fine part promoting unapproved use wellbutrin weight loss sexual european medicines agency ema recommended suspending number nationally approved medicines due misrepresentation bioequivalence study data micro therapeutic research labs products recommended suspension included several mg modifiedrelease bupropion following emas call industrywide review medicines possible presence glaxosmithkline paused batch release distribution bupropion mg tablets november july ema raised acceptable daily intake nitrosamines impurities leading glaxosmithkline announce distribution bupropion mg tablets would resume across eu europe end bupropion demonstrates potential misuse potential less commonly used stimulants limited features case reports describe misuse bupropion producing high similar cocaine amphetamine usage less intensity bupropion misuse number anecdotal casestudy reports bupropion abuse bulk evidence indicates subjective effects bupropion taken orally markedly different addictive stimulants cocaine however bupropion nonconventional routes administration like injection insufflation reported misused united states canada notably russia bupropion banned narcotic drug yet per se rather derivative australia france uk smoking cessation licensed use bupropion generics brand names include wellbutrin aplenzin budeprion buproban forfivo voxra zyban bupron bupisure bupep smoquite elontril buxon stimulants phenylethanolamine httpsenwikipediaorgwikibupropion